Cevec Pharmaceuticals GmbH and Rokote Laboratories Finland Ltd have signed an agreement on the use of Cevec’s proprietary CAP Ad Technology for the manufacturing of vaccines in various indications.
 
Under the agreement, Cevec has granted Rokote Laboratories Finland Ltd non-exclusive rights to use the CAP Ad platform for the manufacturing of adeno-based vaccines for prophylactic and therapeutic use in infectious diseases such as COVID-19, influenza and RSV infections. Cevec in return is eligible to receive license fees, milestone payments, and royalties on net sales.
 
Further financial details were not disclosed.
 
“We are very pleased that Rokote Laboratories Finland Ltd will build on the CAP Ad Technology and we are proud that we can contribute to combating the ongoing COVID-19 pandemic with a technology that makes a real difference in vaccine safety,” said Dr. Nicole Faust, chief executive officer of Cevec. “The quality and safety of vaccines is crucial, given the fact that they are administered prophylactically. Our CAP Ad Technology ensures that the risk of potential adverse effects due to contaminating replication-competent adenovirus is as low as possible.”
 
“Ease of scalability, high production yields, and most importantly, elimination of the risk of RCA contamination were key points why we chose Cevec’s CAP Ad Technology for our adenovirus vector-based large-scale vaccine production,” said Dr. Erkko Ylösmäki, director, Research and Development of Rokote Laboratories Finland. “This technology allows us to rapidly address the global need for a safe and easy-to-administer variant-proof COVID-19 intranasal vaccine that can not only prevent the disease but can also prevent those vaccinated from further transmitting the SARS-CoV-2 virus.”